|
1
|
Buys SS, Sandbach JF, Gammon A, Patel G,
Kidd J, Brown KL, Sharma L, Saam J, Lancaster J and Daly MB: A
study of over 35,000 women with breast cancer tested with a 25-gene
panel of hereditary cancer genes. Cancer. 123:1721–1730.
2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Sun J, Meng H, Yao L, Lv M, Bai J, Zhang
J, Wang L, Ouyang T, Li J, Wang T, et al: Germline mutations in
cancer susceptibility genes in a large series of unselected breast
cancer patient. Clin Cancer Res. 23:6113–6119. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Mavaddat N, Barrowdale D, Andrulis IL,
Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M,
Sherman M, et al: Pathology of breast and ovarian cancers among
BRCA1 and BRCA2 mutation carriers: Results from the Consortium of
Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol
Biomarkers Prev. 21:134–147. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Arai M, Yokoyama S, Watanabe C, Yoshida R,
Kita M, Okawa M, Sakurai A, Sekine M, Yotsumoto J, Nomura H, et al:
Genetic and clinical characteristics in Japanese hereditary breast
and ovarian cancer: First report after establishment of HBOC
registration system in Japan. J Hum Genet. 63:447–457.
2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
NCCN Clinical Practice Guidelines in
Oncology (NCCN Guidelines): Genetic/Familial High-Risk Assessment:
Breast, Ovarian, and Pancreatic. Version 1.2020-December 4, 2019.
NCCN org. http://www.nccn.org/professionals/. Accessed May
2020.
|
|
6
|
Iwase H, Kurebayashi J, Tsuda H, Ohta T,
Kurosumi M, Miyamoto K, Yamamoto Y and Iwase T: Clinicopathological
analyses of triple negative breast cancer using surveillance data
from the Registration Committee of the Japanese Breast Cancer
Society. Breast Cancer. 17:118–124. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Shibuta K, Ueo H, Furusawa H, Komaki K,
Rai Y, Sagara Y, Kamada Y and Tamaki N: The relevance of intrinsic
subtype to clinicopathological features and prognosis in 4,266
Japanese women with breast cancer. Breast Cancer. 18:292–298.
2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kinoshita T, Fukui N, Anan K, Iwamoto T,
Niikura N, Kawai M, Hayashi N, Tsugawa K, Aogi K, Ishida T, et al:
Comprehensive prognostic report of the Japanese Breast Cancer
Society Registry in 2004. Breast Cancer. 23:39–49. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Robson M, Im SA, Senkus E, Xu B, Domchek
SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, et al:
Olaparib for metastatic breast cancer in patients with a Germline
BRCA mutation. N Engl J Med. 377:523–533. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Armstrong N, Ryder S, Forbes C, Ross J and
Quek RG: A systematic review of the international prevalence of
BRCA mutation in breast cancer. Clin Epidemiol. 11:543–561.
2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Emborgo TS, Saporito D, Muse KI, Brrera
AMG, Litton JK, Lu KH and Arun BK: Prospective evaluation of
universal BRCA testing for women with triple-negative breast
cancer. JNCI Cancer Spectr. 4(pkaa002)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Greenup R, Buchanan A, Lorizio W, Rhoads
K, Chan S, Leedom T, King R, McLennan J, Crawford B, Kelly Marcom
P, et al: Prevalence of BRCA mutations among women with
triple-negative breast cancer (TNBC) in a genetic counseling
cohort. Ann Surg Oncol. 20:3254–3258. 2013.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Li YT, Ni D, Yang L, Zhao Q and Ou JH: The
prevalence of BRCA1/2 mutations of triple-negative breast cancer
patients in Xinjiang multiple ethnic region of China. Eur J Med
Res. 19(35)2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Nakamura S, Takahashi M, Tozaki M,
Nakayama T, Nomizu T, Miki Y, Murakami Y, Aoki D, Iwase T,
Nishimura S, et al: Prevalence and differentiation of hereditary
breast and ovarian cancers in Japan. Breast Cancer. 22:462–468.
2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Couch FJ, Hart SN, Sharma P, Toland AE,
Wang X, Miron P, Olson JE, Godwin AK, Pankratz VS, Olswold C, et
al: Inherited mutations in 17 breast cancer susceptibility genes
among a large triple-negative breast cancer cohort unselected for
family history of breast cancer. J Clin Oncol. 33:304–311.
2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sharma P, Klemp JR, Kimler BF, Mahnken JD,
Geier LJ, Khan QJ, Elia M, Connor CS, McGinness MK, Mammen JM, et
al: Germline BRCA mutation evaluation in a prospective
triple-negative breast cancer registry: Implications for hereditary
breast and/or ovarian cancer syndrome testing. Breast Cancer Res
Treat. 145:707–714. 2014.PubMed/NCBI View Article : Google Scholar
|
